Targeted drug delivery, nanotechnology, lipids, liposomes, cancer, metastasis, personalized medicine
Our goal is to improve patients’ quality of life, by developing innovative technologies that advance the way diseases are understood and treated.
The next decade in medicine must make patient-specific care a top priority. Our research aims at tailoring treatments to address each person’s individualized needs and unique disease presentation.
Specifically, our group focuses on improving the treatment of metastatic cancer. Metastasis, the spread of cancer to distant organs, is the cause of 90% of cancer-related deaths. We are developing a nanoscale platform that targets the metastatic sites and then treat them in a precise manner.
Remotely-activated protein-producing nanoparticles . Avi Schroeder, Michael S. Goldberg, Christian Kastrup, Christopher G. Levins, Robert Langer and Daniel G. Anderson. NanoLetters, 2012, 12 (6), 2685–2689. Highlighted in: Nature, 2012, 484, 290.
Treating metastatic cancer with nanotechnology. Avi Schroeder, Daniel A. Heller, Monte M. Winslow, James E. Dahlman, George W. Pratt, Robert Langer, Tyler Jacks and Daniel G. Anderson. Nature Rev. Cancer, 2011, 12(1), 39-50.
Lipid-Based Nanotherapeutics for siRNA Delivery. Avi Schroeder, Christopher G. Levins, Christina Cortez, Robert Langer, Daniel G. Anderson. J. Internal Medicine, 2010, 267(1), 9-21.